Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015141 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
A Phase 2 study of Partial-onset Seizures and Pediatric Epileptic Syndrome, sponsored by Eisai.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT04015141: Recruiting Phase 2 study of Partial-onset Seizures and Pediatric Epileptic Syndrome, sponsored by Eisai.
NCT04015141 is a Phase 2 study of Partial-onset Seizures and Pediatric Epileptic Syndrome that is actively recruiting participants, run by Eisai. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04015141, a Phase 2 study of Partial-onset Seizures and Pediatric Epileptic Syndrome, is actively recruiting participants, sponsored by Eisai.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Primary Outcome
A response of 50% will be defined as a decrease in 28-day seizure frequency of equal or greater than 50% compared to baseline seizure frequency.
Conditions Studied
Interventions
- DRUG Perampanel Oral Suspension
- DRUG Perampanel Tablet
Study Locations (20)
Florida
- Nicklaus Children's Hospital - Miami
- Pediatric Neurology PA - Orlando
- Pediatric Epilepsy and Neurology Specialists - Tampa
Arizona
- Phoenix Childrens Hospital - Phoenix
- Center For Neurosciences - Tucson
Georgia
- PANDA Neurology - Atlanta
- Meridian Clinical Research-(Savannah Georgia) - Savannah
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Dayton Children's Hospital - Dayton
Texas
- Child Neurology Consultants of Austin - Austin
- Road Runner Research Ltd - San Antonio
California
- David Geffen School of Medicine at UCLA - Los Angeles
Colorado
- Childrens Hospital Colorado - Aurora
Delaware
- Nemours Foundation Alfred Dupont Children's Hospital - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-05-31 |
| Est. Completion | 2027-12-23 |
| Phase | Phase 2 |
What NCT04015141 shows while recruiting
NCT04015141 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Partial-onset Seizures appearing as the primary indexed condition, and to 2 interventions - of which Perampanel Oral Suspension is the first listed.
NCT04015141 names 20 study sites across 14 states, led by Florida, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT04015141 about?
NCT04015141 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy". The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
What is the current status of trial NCT04015141?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-05-31. Estimated completion is 2027-12-23.
What conditions does trial NCT04015141 study?
This clinical trial studies the following conditions: Partial-onset Seizures, Pediatric Epileptic Syndrome.
What interventions are being tested in trial NCT04015141?
The interventions under investigation include: Perampanel Oral Suspension (DRUG), Perampanel Tablet (DRUG).
Who is sponsoring clinical trial NCT04015141?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04015141 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial-onset Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04015141's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI